Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1988 Aug;58(2):122–127. doi: 10.1038/bjc.1988.177

Potentiation of the anti-tumour effect of melphalan by the vasoactive agent, hydralazine.

I J Stratford 1, G E Adams 1, J Godden 1, J Nolan 1, N Howells 1, N Timpson 1
PMCID: PMC2246762  PMID: 3166900

Abstract

The vaso-active drug hydralazine causes a considerable increase in the cytotoxic effect of melphalan towards the KHT tumour in mice. The enhancement in response, measured as the concentration of melphalan required to achieve a given tumour response, is 3.0 and 2.35 when determined using the regrowth delay assay and the technique for determining surviving fraction in vitro following treatment in vivo respectively. In contrast, measurement of systemic toxicity shows that the addition of hydralazine only causes a small increase (ER = 1.15) in melphalan damage. This suggests that the drug combination may have some therapeutic benefit. The tumour specificity for the action of hydralazine is supported by the finding that binding of 3H-misonidazole is increased in tumours but not in other tissues when mice are treated with hydralazine. Increased binding of labelled misonidazole is associated with an increase in the level and duration of hypoxia, which will occur as a consequence of changes in tumour blood flow brought about by hydralazine. However, hypoxia per se is not responsible for the enhanced effect of melphalan, since the agent BW12C, which also induces substantial tumour hypoxia as a result of changing the O2 affinity of haemoglobin, has no effect on melphalan tumour cytotoxicity.

Full text

PDF
122

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ALGIRE G. H., LEGALLAIS F. Y. Vascular reactions of normal and malignant tissues in vivo. IV. The effect of peripheral hypotension on transplanted tumors. J Natl Cancer Inst. 1951 Oct;12(2):399–421. [PubMed] [Google Scholar]
  2. Adams G. E., Barnes D. W., du Boulay C., Loutit J. F., Cole S., Sheldon P. W., Stratford I. J., van den Aardweg G. J., Hopewell J. W., White R. D. Induction of hypoxia in normal and malignant tissues by changing the oxygen affinity of hemoglobin--implications for therapy. Int J Radiat Oncol Biol Phys. 1986 Aug;12(8):1299–1302. doi: 10.1016/0360-3016(86)90158-6. [DOI] [PubMed] [Google Scholar]
  3. CATER D. B., GRIGSON C. M., WATKINSON D. A. Changes of oxygen tension in tumours induced by vasoconstrictor and vasodilator drugs. Acta radiol. 1962 Dec;58:401–434. doi: 10.3109/00016926209169582. [DOI] [PubMed] [Google Scholar]
  4. Chan R. C., Babbs C. F., Vetter R. J., Lamar C. H. Abnormal response of tumor vasculature to vasoactive drugs. J Natl Cancer Inst. 1984 Jan;72(1):145–150. doi: 10.1093/jnci/72.1.145. [DOI] [PubMed] [Google Scholar]
  5. Chaplin D. J., Acker B. The effect of hydralazine on the tumor cytotoxicity of the hypoxic cell cytotoxin RSU-1069: evidence for therapeutic gain. Int J Radiat Oncol Biol Phys. 1987 Apr;13(4):579–585. doi: 10.1016/0360-3016(87)90075-7. [DOI] [PubMed] [Google Scholar]
  6. Garrecht B. M., Chapman J. D. The labelling of EMT-6 tumours in BALB/C mice with 14C-misonidazole. Br J Radiol. 1983 Oct;56(670):745–753. doi: 10.1259/0007-1285-56-670-745. [DOI] [PubMed] [Google Scholar]
  7. Kallman R. F., Silini G., Van Putten L. M. Factors influencing the quantitative estimation of the in vivo survival of cells from solid tumors. J Natl Cancer Inst. 1967 Sep;39(3):539–549. [PubMed] [Google Scholar]
  8. Knapp W. H., Debatin J., Layer K., Helus F., Altmann A., Sinn H. J., Ostertag H. Selective drug-induced reduction of blood flow in tumor transplants. Int J Radiat Oncol Biol Phys. 1985 Jul;11(7):1357–1366. doi: 10.1016/0360-3016(85)90252-4. [DOI] [PubMed] [Google Scholar]
  9. Kruuv J. A., Inch W. R., McCredie J. A. Blood flow and oxygenation of tumors in mice. II. Effects of vasodilator drugs. Cancer. 1967 Jan;20(1):60–65. doi: 10.1002/1097-0142(1967)20:1<60::aid-cncr2820200109>3.0.co;2-c. [DOI] [PubMed] [Google Scholar]
  10. Lee F. Y., Workman P. Altered pharmacokinetics in the mechanism of chemosensitization: effects of nitroimidazoles and other chemical modifiers on the pharmacokinetics, antitumour activity and acute toxicity of selected nitrogen mustards. Cancer Chemother Pharmacol. 1986;17(1):30–37. doi: 10.1007/BF00299862. [DOI] [PubMed] [Google Scholar]
  11. Little J. B., Hahn G. M., Frindel E., Tubiana M. Repair of potentially lethal radiation damage in vitro and in vivo. Radiology. 1973 Mar;106(3):689–694. doi: 10.1148/106.3.689. [DOI] [PubMed] [Google Scholar]
  12. McNally N. J., Sheldon P. W. The effect of radiation on tumour growth delay, cell survival and cure of the animal using a single tumour system. Br J Radiol. 1977 May;50(593):321–328. doi: 10.1259/0007-1285-50-593-321. [DOI] [PubMed] [Google Scholar]
  13. Murray J. C., Randhawa V., Denekamp J. The effects of melphalan and misonidazole on the vasculature of a murine sarcoma. Br J Cancer. 1987 Mar;55(3):233–238. doi: 10.1038/bjc.1987.45. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Peacock J. H., Stephens T. C. Influence of anaesthetics on tumour-cell kill and repopulation in B16 melanoma treated with melphalan. Br J Cancer. 1978 Dec;38(6):725–731. doi: 10.1038/bjc.1978.279. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Robinson B. A., Clutterbuck R. D., Millar J. L., McElwain T. J. Effects of verapamil and alcohol on blood flow, melphalan uptake and cytotoxicity, in murine fibrosarcomas and human melanoma xenografts. Br J Cancer. 1986 May;53(5):607–614. doi: 10.1038/bjc.1986.103. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Robinson B. A., Clutterbuck R. D., Millar J. L., McElwain T. J. Verapamil potentiation of melphalan cytotoxicity and cellular uptake in murine fibrosarcoma and bone marrow. Br J Cancer. 1985 Dec;52(6):813–822. doi: 10.1038/bjc.1985.264. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Siemann D. W. Modification of chemotherapy by nitroimidazoles. Int J Radiat Oncol Biol Phys. 1984 Sep;10(9):1585–1594. doi: 10.1016/0360-3016(84)90508-x. [DOI] [PubMed] [Google Scholar]
  18. Stratford I. J., Walling J. M., Silver A. R. The differential cytotoxicity of RSU 1069: cell survival studies indicating interaction with DNA as a possible mode of action. Br J Cancer. 1986 Mar;53(3):339–344. doi: 10.1038/bjc.1986.57. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Thomson J. E., Rauth A. M. An in vitro assay to measure the viability of KHT tumor cells not previously exposed to culture conditions. Radiat Res. 1974 May;58(2):262–276. [PubMed] [Google Scholar]
  20. Van Os-Corby D. J., Chapman J. D. In vitro binding of 14C-misonidazole to hepatocytes and hepatoma cells. Int J Radiat Oncol Biol Phys. 1986 Jul;12(7):1251–1254. doi: 10.1016/0360-3016(86)90270-1. [DOI] [PubMed] [Google Scholar]
  21. Voorhees W. D., 3rd, Babbs C. F. Hydralazine-enhanced selective heating of transmissible venereal tumor implants in dogs. Eur J Cancer Clin Oncol. 1982 Oct;18(10):1027–1033. doi: 10.1016/0277-5379(82)90252-8. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES